At a glance
- Originator Sanofi-Synthelabo
- Class
- Mechanism of Action Cannabinoid receptor CB2 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Obesity
Most Recent Events
- 17 Dec 2003 No development reported - Preclinical for Obesity in France (unspecified route)
- 26 Sep 2001 New profile
- 26 Sep 2001 Preclinical development for Obesity in France (Unknown route)